Marketing of unproven stem cell-based interventions: A call to action

Douglas Sipp, Timothy Caulfield, Jane Kaye, Jan Barfoot, Clare Blackburn, Sarah Chan, Michele De Luca, Alastair Kent, Christopher McCabe, Megan Munsie, Margaret Sleeboom-Faulkner, Jeremy Sugarman, Esther van Zimmeren, Amy Zarzeczny, John E J Rasko

Research output: Contribution to journalArticlepeer-review

Abstract

Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.

Original languageEnglish
JournalScience Translational Medicine
Volume9
Issue number397
DOIs
Publication statusPublished - 5 Jul 2017

Keywords

  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'Marketing of unproven stem cell-based interventions: A call to action'. Together they form a unique fingerprint.

Cite this